Categories: News

Psychedelic Healthcare Innovation: PsiloThera Announces Launch of Quantum Technology Drug Development Program

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HENDERSON, Nev., July 30, 2021 /PRNewswire/ — PsiloThera, Inc. is a pioneering Psychedelic Healthcare Innovation & Life Sciences Company developing Psilocybin (“Magic Mushroom”) based Drugs and Therapies proudly announces the launch of its Quantum Technology Drug Development Program.

“Quantum Technology could ultimately change the way that Humans digest supplements, medications and nutrients.”

PsiloThera’s Clinical Focus is the Treatment of Mental Illnesses including: Depression, Anxiety, PTSD, Eating Disorders & Addictions and Cognitive Diseases & Neurological Disorders such as Alzheimer’s, Dementia and Autism.

PsiloThera’s specialized treatment programs will provide care for Vets, 1st Responders & Patients with Treatment Resistant Mental Illnesses.

PsiloThera CEO, John Atanasio states,”PsiloThera is among the first companies focused on developing novel therapeutics by deploying Quantum Technology that can collect and send materials through organic devices.”

“PsiloThera’s strategy is to have its products lead the future of energy-based nutrients and medication delivery systems.”  “Quantum technology may lead to advances that could ultimately change the way that Humans digest supplements, medications and nutrients.”

“Our Quantum Technology Advisors projects that the technology projects to deliver significant improvements in areas  of Pharmaceutical dispensing issues and adverse effects.”

“Quantum Technology may lead to significant reductions in drug development time and costs, giving PsiloThera a possible major competitive advantage if that were to prove true”

The Journal of American Medical Association- “JAMA PSYCHIATRY” reported in a 2020 study that a treatment of Psilocybin “Magic Mushrooms” works much better than usual anti-depressant medications.

PsiloThera’s outstanding battle tested management team will operate the Company’s  vertical business model  which includes; Fungi Grow, Research & Development, Drug Development, Tele-Mental Health Platform and PsiloThera Treatment Centers.

PsiloThera just launched a Crowdfund Campaign @  www.startengine.com/psilothera 

Start Engine’s spokesperson is non-other than Shark Tank’s TV Show Personality, “Mr. Wonderful” Kevin O’Leary.

Source & Contacts: PsiloThera Inc.   john@psilothera.com    sara@startengine.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/psychedelic-healthcare-innovation-psilothera-announces-launch-of-quantum-technology-drug-development-program-301345163.html

SOURCE PsiloThera Inc.

Staff

Recent Posts

Evidently Hires Andrés Krogh-Walker as Head of Marketing

The clinical data intelligence platform continues executive team expansion following $15 million funding round PALO…

18 minutes ago

Quantum Sensors Market to Hit USD 839 Million by 2031 | Key Growth in Defense, Healthcare & IT – Valuates Reports

BANGALORE, India, May 23, 2025 /PRNewswire/ -- Quantum Sensors Market is Segmented by Type (Atomic…

20 minutes ago

RED DOOR COMMUNITY LAUNCHES NEW “COMMUNITY CONNECTIONS” BLOG AS A RESOURCE FOR THOSE IMPACTED BY CANCER

This new platform offers an opportunity to share expert insights, common experiences, and inspirations as…

20 minutes ago

AI Could Add $461 Billion to Global Healthcare–And These New Platforms Are Leading the Charge

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 23,…

20 minutes ago

Perrigo to Attend the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference

DUBLIN, May 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of…

20 minutes ago

O’Shaughnessy Ventures Backs AI-Powered Dream Reconstruction

Ninon Lizé Masclef awarded $100,000 fellowship to turn brain-wave data into 3D visualizations of dreams GREENWICH,…

20 minutes ago